A phase III study of icatibant in patients with acute attacks of hereditary angioedema (HAE)

Trial Profile

A phase III study of icatibant in patients with acute attacks of hereditary angioedema (HAE)

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Icatibant (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Dec 2015 According to a Shire media release, Shire plans to initiate this study in 2016.
    • 27 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top